1. Home
  2. ANL vs NEPH Comparison

ANL vs NEPH Comparison

Compare ANL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.42

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$5.09

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
NEPH
Founded
2004
1997
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.0M
60.0M
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
ANL
NEPH
Price
$1.42
$5.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
31.4K
67.7K
Earning Date
04-20-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.14
Revenue
N/A
$17,930,000.00
Revenue This Year
N/A
$33.32
Revenue Next Year
N/A
$12.27
P/E Ratio
N/A
$36.23
Revenue Growth
N/A
32.36
52 Week Low
$0.88
$1.39
52 Week High
$2.99
$6.42

Technical Indicators

Market Signals
Indicator
ANL
NEPH
Relative Strength Index (RSI) 49.96 49.99
Support Level $1.42 $4.80
Resistance Level $1.70 $5.97
Average True Range (ATR) 0.18 0.42
MACD 0.04 -0.03
Stochastic Oscillator 65.39 42.04

Price Performance

Historical Comparison
ANL
NEPH

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: